ZBIO earnings date and last-quarter result: next report 2026-08-11, last quarter miss, P/E -3.46. Updated 2026-07-23.
Zenas BioPharma (ZBIO) Research Hub
Zenas BioPharma (ZBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 27.24 USD (+1.38%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.46, market cap 1.42B. This hub links to the full technical, earnings and options research available for ZBIO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 27.24 USD (+1.38%) |
| 52-week range | 18.06 USD – 33.99 USD |
| Trend regime | Range |
| 14-day RSI | 51.2 (Neutral) |
| Trailing P/E | -3.46 |
| Market cap | 1.42B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ZBIO
Covered Call on ZBIO: how it works, illustrative setup around the real 27.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ZBIO: how it works, illustrative setup around the real 27.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ZBIO: how it works, illustrative setup around the real 27.24 USD price, max profit/loss, breakeven and when to use it. Educational.
ZBIO technical analysis: range, last 27.24 USD, RSI 51.2, 52w range 18.06 USD–33.99 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ZBIO in?
Zenas BioPharma (ZBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ZBIO in an uptrend or downtrend?
As of 2026-10-26, ZBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ZBIO's trailing P/E ratio?
ZBIO's trailing P/E is -3.46, with a market cap of 1.42B. See the earnings research page for full valuation detail.
When does ZBIO next report earnings?
ZBIO is next scheduled to report earnings on 2026-08-11.